Tango Therapeutics has received FDA clearance on its Investigational New Drug application for TNG348. TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD+ cancers, including BRCA1/2 mutations, represent up to 50% of ovarian cancers, 25% of breast cancers, 10% of prostate cancers and 5% of pancreatic cancers. TNG348 is a USP-1 inhibitor developed from the preclinical USP-1 program in-licensed from Medivir in 2020.

Under the licensing agreement, Medivir is entitled to multiple development and commercial milestone payments as well as royalties on future sales.